Gianfranco Umberto Meduri

Prof. Dr. Gianfranco Umberto Meduri

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2015 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
Gianfranco Umberto MeduriGianfranco Umberto Meduri
Gianfranco Umberto Meduri
LBLisa Bridges
Lisa Bridges
MSMei-Chiung Shih
Mei-Chiung Shih
PMPaul E. Marik
Paul E. Marik
RSReed A. C. Siemieniuk
Reed A. C. Siemieniuk
MKMehmet Kocak
Mehmet Kocak

13 May 2022 in Intensive Care Medicine
Verified
Journal Article
Open access
PDF file
Gianfranco Umberto MeduriGianfranco Umberto Meduri
Gianfranco Umberto Meduri
MSMei-Chiung Shih
Mei-Chiung Shih
LBLisa Bridges
Lisa Bridges
TMThomas J. Martin
Thomas J. Martin
AEAli El-Solh
Ali El-Solh
GHGrant D. Huang
Grant D. Huang
Purpose Severe community-acquired pneumonia (CAP) requiring intensive care unit admission is associated with significant acute and long-term morbidity and mortality. We hypothesized that downregulation of systemic and pulmonary inflammation with prolonged low-dose methylprednisolone treatment would accelerate pneumonia resolution and improve clinical outcomes. Methods This double-blind, randomized, placebo-controlled clinical trial recruited adult patients within 72–96 h of hospital presentation. Patients were randomized in 1:1 ratio; an intravenous 40 mg loading bolus was followed by 40 mg/day through day 7 and progressive tapering during the 20-day treatment course. Randomization was stratified by site and need for mechanical ventilation (MV) at the time of randomization. Outcomes included a primary endpoint of 60-day all-cause mortality and secondary endpoints of morbidity and mortality up to 1 year of follow-up. Results Between January 2012 and April 2016, 586 patients from 42 Veterans Affairs Medical Centers were randomized, short of the 1420 target sample size because of low recruitment. 584 patients were included in the analysis. There was no significant difference in 60-day mortality between the methylprednisolone and placebo arms (16% vs. 18%; adjusted odds ratio 0.90, 95% CI 0.57–1.40). There were no significant differences in secondary outcomes or complications. Conclusions In patients with severe CAP, prolonged low-dose methylprednisolone treatment did not significantly reduce 60-day mortality. Treatment was not associated with increased complications.

15 October 2016 in Critical Care
Verified
Journal Article
Open access
PDF file
STSurat Tongyoo
Surat Tongyoo
CPChairat Permpikul
Chairat Permpikul
WMWasineenart Mongkolpun
Wasineenart Mongkolpun
VVVeerapong Vattanavanit
Veerapong Vattanavanit
SUSuthipol Udompanturak
Suthipol Udompanturak
Gianfranco Umberto MeduriGianfranco Umberto Meduri
Gianfranco Umberto Meduri
Authors of recent meta-analyses have reported that prolonged glucocorticoid treatment is associated with significant improvements in patients with severe pneumonia or acute respiratory distress syndrome (ARDS) of multifactorial etiology. A prospective randomized trial limited to patients with sepsis-associated ARDS is lacking. The objective of our study was to evaluate the efficacy of hydrocortisone treatment in sepsis-associated ARDS. In this double-blind, single-center (Siriraj Hospital, Bangkok), randomized, placebo-controlled trial, we recruited adult patients with severe sepsis within 12 h of their meeting ARDS criteria. Patients were randomly assigned (1:1 ratio) to receive either hydrocortisone 50 mg every 6 h or placebo. The primary endpoint was 28-day all-cause mortality; secondary endpoints included survival without organ support on day 28. Over the course of 4 years, 197 patients were randomized to either hydrocortisone (n = 98) or placebo (n = 99) and were included in this intention-to-treat analysis. The treatment group had significant improvement in the ratio of partial pressure of oxygen in arterial blood to fraction of inspired oxygen and lung injury score (p = 0.01), and similar timing to removal of vital organ support (HR 0.74, 95 % CI 0.51–1.07; p = 0.107). After adjustment for significant covariates, day 28 survival was similar for the whole group (HR 0.80, 95 % CI 0.46–1.41; p = 0.44) and for the larger subgroup (n = 126) with Acute Physiology and Chronic Health Evaluation II score <25 (HR 0.57, 95 % CI 0.24–1.36; p = 0.20). With the exception of hyperglycemia (80.6 % vs. 67.7 %; p = 0.04), the rate of adverse events was similar. Hyperglycemia had no impact on outcome. In sepsis-associated ARDS, hydrocortisone treatment was associated with a significant improvement in pulmonary physiology, but without a significant survival benefit. ClinicalTrials.gov identifier NCT01284452 . Registered on 18 January 2011.

22 April 2021 in American Journal of Therapeutics
Verified
Journal Article
Open access
PKPierre Kory
Pierre Kory
Gianfranco Umberto MeduriGianfranco Umberto Meduri
Gianfranco Umberto Meduri
JVJoseph Varon
Joseph Varon
JIJose Iglesias
Jose Iglesias
PMPaul E. Marik
Paul E. Marik
Background: After COVID-19 emerged on U.S shores, providers began reviewing the emerging basic science, translational, and clinical data to identify potentially effective treatment options. In addition, a multitude of both novel and repurposed therapeutic agents were used empirically and studied within clinical trials. Areas of Uncertainty: The majority of trialed agents have failed to provide reproducible, definitive proof of efficacy in reducing the mortality of COVID-19 with the exception of corticosteroids in moderate to severe disease. Recently, evidence has emerged that the oral antiparasitic agent ivermectin exhibits numerous antiviral and anti-inflammatory mechanisms with trial results reporting significant outcome benefits. Given some have not passed peer review, several expert groups including Unitaid/World Health Organization have undertaken a systematic global effort to contact all active trial investigators to rapidly gather the data needed to grade and perform meta-analyses. Data Sources: Data were sourced from published peer-reviewed studies, manuscripts posted to preprint servers, expert meta-analyses, and numerous epidemiological analyses of regions with ivermectin distribution campaigns. Therapeutic Advances: A large majority of randomized and observational controlled trials of ivermectin are reporting repeated, large magnitude improvements in clinical outcomes. Numerous prophylaxis trials demonstrate that regular ivermectin use leads to large reductions in transmission. Multiple, large “natural experiments” occurred in regions that initiated “ivermectin distribution” campaigns followed by tight, reproducible, temporally associated decreases in case counts and case fatality rates compared with nearby regions without such campaigns. Conclusions: Meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance. Furthermore, results from numerous controlled prophylaxis trials report significantly reduced risks of contracting COVID-19 with the regular use of ivermectin. Finally, the many examples of ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an oral agent effective in all phases of COVID-19 has been identified.

4 November 2020 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
Gianfranco Umberto MeduriGianfranco Umberto Meduri
Gianfranco Umberto Meduri
DADjillali Annane
Djillali Annane
MCMarco Confalonieri
Marco Confalonieri
GCGeorge P. Chrousos
George P. Chrousos
BRBram Rochwerg
Bram Rochwerg
BMBernd Meibohm
Bernd Meibohm

24 August 2018 in Journal of Intensive Care
Verified
Journal Article
Open access
PDF file
Gianfranco Umberto MeduriGianfranco Umberto Meduri
Gianfranco Umberto Meduri
RSReed A. C. Siemieniuk
Reed A. C. Siemieniuk
RNRachel A. Ness
Rachel A. Ness
SSSamuel J. Seyler
Samuel J. Seyler
An updated meta-analysis incorporating nine randomized trials (n = 816) investigating low-to-moderate dose prolonged glucocorticoid treatment in acute respiratory distress syndrome (ARDS) show moderate-to-high quality evidence that glucocorticoid therapy is safe and reduces (i) time to endotracheal extubation, (ii) duration of hospitalization, and (iii) mortality (number to treat to save one life = 7), and increases the number of days free from (i) mechanical ventilation, (ii) intensive care unit stay, and (iii) hospitalization. Recent guideline suggests administering methylprednisolone in patients with early moderate-to-severe (1 mg/kg/day) and late persistent (2 mg/kg/day) ARDS (conditional recommendation based on moderate quality of evidence).